Glaxit: Flagging a looming threat from Gilead and a weak pipeline, Neil Woodford is giving up on GSK and pulling out
After watching GlaxoSmithKline grow increasingly hampered by a weak pipeline and “stretched” financials, longtime investor Neil Woodford has decided to quit the pharma giant, worried that a rival HIV therapy from Gilead may soon cripple ViiV, the pharma giant’s one bright spot.
In a lengthy blog post today titled Glaxit, Woodford noted that he’s been advising the company for years now to split up and do something positive for investors. Former CEO Andrew Witty, though, rejected the suggestions and new CEO Emma Walmsley seems set on the same path.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.